Toft Group Completes Executive Search for aTyr Pharma, Inc. (Nasdaq: LIFE) in San Diego, CA
Executive search firm Toft Group has placed Dr. Naresh Nayyar, PhD, MBA, RAC. as Associate Vice President, Regulatory & Quality Affairs at aTyr Pharma, Inc. (Nasdaq: LIFE) in San Diego, CA. Dr. Nayyar is a proven Global Regulatory Affairs professional with experience leading and implementing regulatory strategies for novel pharmaceutical approvals. Dr. Nayyar previously served as Sr. Director of Regulatory Affairs at Halozyme. He holds a Ph.D. degree in Organic Chemistry from the University of Delhi in Delhi, India.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD. To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.